Cargando…
Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Despite the development of multimodality treatments, including surgical resection, radiotherapy, and chemotherapy, the long-term prognosis of patients with PDAC remains poor. Recently, the introduction of neoadjuvant treatmen...
Autores principales: | Zhang, Yun, Huang, Zi-Xing, Song, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192284/ https://www.ncbi.nlm.nih.gov/pubmed/34168406 http://dx.doi.org/10.3748/wjg.v27.i22.3037 |
Ejemplares similares
-
Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021) -
Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma
por: Hu, Xiu, et al.
Publicado: (2021) -
Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017) -
Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: Caba, Octavio, et al.
Publicado: (2023) -
Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)